BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...with data available in early 2023. The series A provides runway to mid-2023. New investors Morningside Venture Investments...
...and more Corporate partners: N/A Number of employees: 10-20 Funds raised: $84.5 million Investors: Forbion, Morningside Venture Investments...
BioCentury | Jan 31, 2019
Emerging Company Profile

Apic: Dual-gene therapies

...School. On Jan. 7, Apic raised $40 million in a series A round led by Morningside Venture Investments...
...Massachusetts Medical School Corporate partners: Undisclosed Number of employees: Undisclosed Funds raised: $43 million Investors: Morningside Venture Investments...
BioCentury | Jan 11, 2019
Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

...preclinical programs and support discovery efforts for the company's gene silencing and replacement THRIVE platform. Morningside Venture Investments...
BioCentury | Jan 8, 2019
Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

...preclinical programs and support discovery efforts for the company's gene silencing and replacement THRIVE platform. Morningside Venture Investments...
BioCentury | Jun 8, 2018
Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

...Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners, Morningside Venture Investments...
BioCentury | Jun 4, 2018
Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

...Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners, Morningside Venture Investments...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

...is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments...
...p300 (EP300; p300) and CREB binding protein (CREBBP; CBP). CellCentric Ltd., Little Chesterford, U.K. Mark Zipkin CCS1477 CellCentric Ltd. Morningside Venture Investments Prostate...
BioCentury | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments...
...inhibitor of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP). Mark Zipkin CCS1477 CellCentric Ltd. Morningside Venture Investments Prostate...
BioCentury | Oct 17, 2016
Financial News

TransThera completes venture financing

...Nanjing, China Business: Cancer, Cardiovascular Date completed: 2016-10-13 Type: Venture financing Raised: $10 million Investors: Morningside Venture Investments...
Items per page:
1 - 10 of 29
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...with data available in early 2023. The series A provides runway to mid-2023. New investors Morningside Venture Investments...
...and more Corporate partners: N/A Number of employees: 10-20 Funds raised: $84.5 million Investors: Forbion, Morningside Venture Investments...
BioCentury | Jan 31, 2019
Emerging Company Profile

Apic: Dual-gene therapies

...School. On Jan. 7, Apic raised $40 million in a series A round led by Morningside Venture Investments...
...Massachusetts Medical School Corporate partners: Undisclosed Number of employees: Undisclosed Funds raised: $43 million Investors: Morningside Venture Investments...
BioCentury | Jan 11, 2019
Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

...preclinical programs and support discovery efforts for the company's gene silencing and replacement THRIVE platform. Morningside Venture Investments...
BioCentury | Jan 8, 2019
Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

...preclinical programs and support discovery efforts for the company's gene silencing and replacement THRIVE platform. Morningside Venture Investments...
BioCentury | Jun 8, 2018
Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

...Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners, Morningside Venture Investments...
BioCentury | Jun 4, 2018
Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

...Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners, Morningside Venture Investments...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

...is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments...
...p300 (EP300; p300) and CREB binding protein (CREBBP; CBP). CellCentric Ltd., Little Chesterford, U.K. Mark Zipkin CCS1477 CellCentric Ltd. Morningside Venture Investments Prostate...
BioCentury | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments...
...inhibitor of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP). Mark Zipkin CCS1477 CellCentric Ltd. Morningside Venture Investments Prostate...
BioCentury | Oct 17, 2016
Financial News

TransThera completes venture financing

...Nanjing, China Business: Cancer, Cardiovascular Date completed: 2016-10-13 Type: Venture financing Raised: $10 million Investors: Morningside Venture Investments...
Items per page:
1 - 10 of 29